<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02101580</url>
  </required_header>
  <id_info>
    <org_study_id>POLARIS2013-002</org_study_id>
    <nct_id>NCT02101580</nct_id>
  </id_info>
  <brief_title>Ph 1B Trial With ADI-PEG 20 Plus Nab-Paclitaxel and Gemcitabine in Subjects With Pancreatic Cancer</brief_title>
  <official_title>Phase 1B Trial of ADI-PEG 20 Plus Nab-Paclitaxel and Gemcitabine in Subjects With Advanced Pancreatic Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Polaris Group</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Polaris Group</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Assessment of safety and tolerability of ADI-PEG 20 plus nab-Paclitaxel and Gemcitabine in&#xD;
      subjects with Advanced Pancreatic Carcinoma.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 17, 2014</start_date>
  <completion_date type="Actual">October 6, 2017</completion_date>
  <primary_completion_date type="Actual">May 5, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with Adverse Events as a Measure of Safety and Tolerability of ADI-PEG 20 in combination with nab-Paclitaxel and Gemcitabine in Advanced Pancreatic Cancer</measure>
    <time_frame>course of study - 1 year expected</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">21</enrollment>
  <condition>Advanced Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>ADI-PEG 20</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ADI-PEG 20</intervention_name>
    <arm_group_label>ADI-PEG 20</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Histologically or cytologically confirmed diagnosis of pancreatic carcinoma (dose&#xD;
             escalation and MTD expansion components).&#xD;
&#xD;
          2. Subjects in the dose-escalation component can have had up to 1 prior line of systemic&#xD;
             therapy. Subjects with pancreatic carcinoma to be enrolled in the MTD expansion cohort&#xD;
             must have untreated, measurable metastatic disease. Subjects for the MTD cohort may&#xD;
             have received prior adjuvant gemcitabine or fluoropyrimidine based therapy in the&#xD;
             adjuvant setting provided more than 6 months has elapsed following completion of&#xD;
             adjuvant therapy.&#xD;
&#xD;
          3. Unresectable disease or subject refused surgery.&#xD;
&#xD;
          4. Progressive disease if treated with chemotherapy, radiotherapy, surgery or&#xD;
             immuno-therapy. If prior radiation was given, the measurable disease should be outside&#xD;
             the radiation port.&#xD;
&#xD;
          5. Measurable disease as assessed by RECIST 1.1 criteria (Appendix A).&#xD;
&#xD;
          6. Age ≥ 18 years.&#xD;
&#xD;
          7. ECOG performance status of 0 - 1.&#xD;
&#xD;
          8. No prior systemic therapy, immunotherapy, investigational agent, or radiation therapy&#xD;
             within the last 4 weeks. Radiation therapy for symptomatic relief is allowed within&#xD;
             the last 2 weeks.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Serious infection requiring treatment with systemically administered antibiotics at&#xD;
             the time of study entrance, or an infection requiring systemic antibiotic therapy&#xD;
             within 7 days prior to the first dose of study treatment.&#xD;
&#xD;
          2. Serious underlying lung function abnormality due to the risk of fatal pneumonitis that&#xD;
             was caused by the combination of Abraxane and gemcitabine&#xD;
&#xD;
          3. Grade 2 or higher neuropathy (CTCAE V4.0)&#xD;
&#xD;
          4. Prior treatment with nab-paclitaxel.&#xD;
&#xD;
          5. Pregnancy or lactation.&#xD;
&#xD;
          6. Expected non-compliance.&#xD;
&#xD;
          7. Uncontrolled intercurrent illness including, but not limited to, ongoing or active&#xD;
             infection, symptomatic congestive heart failure (New York Heart Association Class III&#xD;
             or IV), cardiac arrhythmia, or psychiatric illness, social situations that would limit&#xD;
             compliance with study requirements.&#xD;
&#xD;
          8. Subjects who have had any anticancer treatment prior to entering the study and have&#xD;
             not recovered to baseline (except alopecia) or ≤ Grade 1 AEs, or deemed irreversible&#xD;
             from the effects of prior cancer therapy. AEs &gt; Grade 1 that are not considered a&#xD;
             safety risk by the Sponsor and investigator may be allowed upon agreement with both,&#xD;
             including residual neuropathy.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maeve Lowery, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan-Kettering Cancer Center (MSKCC)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>March 25, 2014</study_first_submitted>
  <study_first_submitted_qc>April 1, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 2, 2014</study_first_posted>
  <last_update_submitted>September 30, 2020</last_update_submitted>
  <last_update_submitted_qc>September 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 1, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>argininosuccinate synthetase</keyword>
  <keyword>arginine</keyword>
  <keyword>arginine deiminase</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

